dermatology summit logo

Hyatt Regency, San Francisco, CA
January 8, 2023

REGISTER NOW

The mission of the Dermatology Summit is to build a community of people who are excited about innovation in dermatology.

This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.

Speakers | Program | People | Sponsors | FAQ

Dermatology Summit 2023 Speakers

Frederick Beddingfield, III, MD, PhD, FAAD

Chief Executive Officer
Kira Pharmaceuticals
Associate Clinical Professor of Medicine, Division of Dermatology
David Geffen School of Medicine at UCLA

View Biography

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.

Christophe Bourdon
Christophe Bourdon

Chief Executive Officer
LEO Pharma

View Biography

Mr. Bourdon joined LEO Pharma A/S as CEO in April 2022 coming from a similar position at Orphazyme A/S. During his 25 years in the pharmaceutical industry across 3 continents, Bourdon’s focus has been to build strong and diverse teams, while fostering an environment focused on innovation and curiosity with one constant driver in mind: Making a meaningful difference for patients.

Earlier in his career, Bourdon held a series of leadership roles at Amgen, including Senior Vice President and General Manager for the U.S. Oncology Business, with ten marketed portfolios comprising one of the company’s largest businesses. During his tenure in the US, Bourdon helped launching 3 oncology products, managed to launch 2 biosimilars, and accelerated Amgen’s pipeline focus on new innovative cancer medicine.

Earlier, Bourdon was Vice President and General Manager for Amgen, Germany. He also worked at Alexion as Senior Vice President, EMEAC, leading the commercial development of ultra-orphan therapies across 40 countries.

He earned his MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland, and a BA from the Institut Superieur de Gestion, Paris, France.

Michael Cameron, MD
Michael Cameron, MD

Assistant Professor
Mount Sinai Health System

View Biography

Dr. Cameron is an Assistant Professor in the Department of Dermatology at Mount Sinai in New York. He is a board-certified dermatologist with expertise in drug development and inflammatory skin diseases with previous experience in the pharmaceutical industry and healthcare consulting. He is a consultant for various biotech and pharmaceutical companies. He completed his residency training at MSKCC and the University of Colorado. Prior to residency training, he received his undergraduate degree from Duke University and his medical degree from the University of South Florida.

Previously a medical director at Pfizer, he has expertise in the treatment of eczema, psoriasis, alopecia areata and other types of hair loss, vitiligo, acne, and skin cancer, as well as in performing various cosmetic treatments including botox, fillers, lasers, microneedling, PRP, and chemical peels. He is co-author of more than 20 publications in peer-reviewed medical journals and 2 dermatology textbook chapters.

Matt Davidson, PhD
Matt Davidson, PhD

Co-Founder and Chief Executive Officer
Azora Therapeutics

View Biography

Matt Davidson PhD is cofounder and CEO of Azora Therapeutics, a company developing best-in-class aryl hydrocarbon receptor agonists (AhR) for serious diseases. Prior to founding Azora, Dr. Davidson founded and ran Verrica Pharmaceuticals (Nasdaq: VRCA) a dermatology focused pharmaceutical company developing therapies for common skin diseases after a personal experience with a wart on his finger that would not respond to treatment. Dr. Davidson ran Verrica as CEO and chairman of the board from inception until the decision to go public, leading the company from preclinical into successful pivotal P3 clinical trials raising over $100M in the process.

After graduating from UC Berkeley with high distinction in molecular and cellular biology, Dr. Davidson earned his PhD in Immunology from the Stanford University School of Medicine. Dr. Davidson is the inventor of 6 issued patents and author of numerous scientific publications in high impact journals such as JAMA Dermatology, Nature and the Lancet. He is the recipient of the 2019 Biocom Catalyst Award for life science trailblazers.

Irina Erenburg, PhD
Irina Erenburg, PhD

President & CEO
AVAVA, Inc

View Biography

Dr. Irina Erenburg is the President & CEO of AVAVA, Inc – a company dedicated to developing breakthrough aesthetic products for treatment of all skin tones and types. AVAVA was created from Blossom Innovations, LLC – a discovery and development company that Dr. Erenburg continues to lead since co-founding it in 2011. Dr. Erenburg is a serial entrepreneur, with extensive experience in innovation business leadership. She is the co-founder and board member of R2 Technology and Soltego, Inc and has recently joined the Board of Directors of Sientra, a publicly traded company in the field of breast augmentation and reconstruction. Prior to her role at Blossom and AVAVA, she was the Director of Strategic Transactions at the Partners HealthCare Office of Innovations, Boston’s largest hospital network and a teaching affiliate of Harvard University. There, she was responsible for execution and management of high-value deals and launch of several successful start-ups, including Zeltiq Aesthetics. Dr. Erenburg holds a Ph.D. in Biomedical Science from the Mount Sinai School of Medicine in NY.

Cohava Gelber, PhD, MBA
Cohava Gelber, PhD, MBA

Founder, President and Chief Executive Officer
Serpin Pharma

View Biography

Dr. Gelber is an executive with over 25 years of experience in discovery and drug development of immune therapeutics and diagnostics. Dr. Gelber has held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation).

Prior to founding Serpin Pharma, Dr. Gelber served as the Chief Scientific & Technology Officer of ATCC and supervised a large group of translational research scientists. Dr. Gelber’s group during her tenure at ATCC was awarded ~ $500MM in grants and contracts. Prior to ATCC, Dr. Gelber served as the VP of R&D for MannKind Corp (MNKD) and supervised nonclinical research & safety support to MNKD’s clinical trials for Afrezza. Dr. Gelber received her Ph.D. from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University. She has published numerous scientific manuscripts and textbook chapters and is the inventor of 28 granted patents and 72 patent applications.

Hervé Hoppenot
Hervé Hoppenot

Chairman, President and Chief Executive Officer
Incyte

View Biography

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015.

During Mr. Hoppenot’s tenure, the company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation & Autoimmunity. Under his leadership, revenue has increased by nearly 600% which includes the addition of five new sources of potential revenue. With a goal to deliver medicines to patients worldwide, Incyte has expanded geographically and has operations in North America, Europe and Asia.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. He began his career at Novartis in 2003 as Chief Commercial Officer and later became President in 2010. Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Caroline (Caro) Van Hove
Caroline (Caro) Van Hove

President and Chief Executive Officer
Revelle Aesthetics

View Biography

Ms. Van Hove is a global commercial leader with over 20 years of diverse experience in the pharmaceutical, consumer and medical device industry. Her experience spans North America to Europe, Africa, the Middle East to Asia Pacific and Latin America. Ms. Van Hove is currently President and CEO of Revelle Aesthetics, a venture-backed, medical aesthetics company, and previously held several commercial leadership roles at both start-up and large-cap companies.

Ms. Van Hove also serves as Executive Chair on the Board of Directors of Sientra, a publicly traded medical aesthetics company specialized in breast aesthetics. And she is a proud member of the Board of Directors of Mission Plasticos, a global non-profit dedicated to providing reconstructive surgery to children in need.

Ms. Van Hove previously served as Chief Commercial Officer of Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on therapies in immunology and inflammation. Prior to Sienna, Ms. Van Hove was Senior Vice President of International Strategic Marketing at Allergan, where she oversaw commercial operations for the medical aesthetics, eye care and specialty care franchises. Previously, Ms. Van Hove managed sales & marketing, customer service and customer excellence in Europe, Africa and the Middle East and led Allergan’s international medical aesthetics operations.

Ms. Van Hove is a proud mom of three little girls and wife to a firefighter, residing with her family in Nashville, TN.

Kim D. Kjoeller, MD
Kim D. Kjoeller, MD

Chief Executive Officer
UNION therapeutics

View Biography

Since January 2021, Dr. Kim Kjoeller has served as the CEO at UNION therapeutics. He brings more than 20 years of experience from various executive positions in the pharmaceutical industry of which the last 12 years is within dermatology. Before joining UNION, Dr. Kjoeller held positions at Sanofi, Lundbeck, Sanofi Pasteur MSD and LEO Pharma across R&D, commercial and general management. From 2015 until 2021, Dr. Kjoeller served as Executive Vice President R&D at LEO Pharma.

After graduating from the Copenhagen Medical Faculty in 1994, Dr. Kjoeller held several positions at Copenhagen University Hospital in medicine and surgery until joining Danish Cancer Society, Institute for Epidemiologic Cancer Research in 1996. Dr. Kjoeller is the chairman of the Danish Life Science Cluster, an organization established to foster collaboration between academia, business, communities and regions to jointly progress innovation and improve health care delivery in Denmark.

Dr. Kjoeller is author/co-author of 35+ scientific publications, and has given lectures at Scientific Meetings in Denmark and the Nordics as well as at Pharma Industry Meetings in Europe and the US.

Todd Krueger
Todd Krueger

President & Chief Executive Officer
AOBiome Therapeutics, Inc

View Biography

Todd Krueger is the Chief Executive Officer, President and a Director of AOBiome Therapeutics. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Phi Beta Kappa from Northwestern University with a Bachelor of Economics and earned his MBA from the Kellogg School of Management.

Mr. Krueger has over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008)), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform.

Mr. Krueger is also on the Board of Directors at Neofluidics, a manufacturer of instrumentation for lipid nanoparticles, Tenza, a spinout of George Church’s lab focused on delivering drugs to mucosal surfaces using proprietary bacterial secretion technology, and Isolation Bio, a microbiome tools company based in the United States.

Jesper J. Lange
Jesper J. Lange

Chief Executive Officer
MC2 Therapeutics A/S

View Biography

Jesper J. Lange holds a Master of Law (LLM) degree from Columbia University Law School in New York and is co-founder of MC2 Therapeutics. He joined the company from his position as M&A partner in a major Danish law firm.

Based on his leadership and strong entrepreneurial skills Jesper is focused on bringing together the expertise of people and companies through a fundamental belief in inclusion and diversity as the main driver of passion, innovation and high performance.

Douglas Maslin, MPhil, MA, MB BChir
Douglas Maslin, MPhil, MA, MB BChir

Vice President, Late-Stage Clinical Lead
Evelo Biosciences

View Biography

Dr. Douglas Maslin is VP and Clinical Lead at Evelo Biosciences. Douglas is responsible for the clinical strategy and execution of the EDP1815 program, which includes an ongoing phase 2 study in atopic dermatitis and planning for phase 3 in psoriasis.
Douglas is also a practicing physician in Dermatology at Addenbrooke’s Hospital, Cambridge, UK, with weekly clinics across dermatology. He has a special interest in novel treatments for immunoinflammatory skin diseases.

Douglas graduated with distinction from Cambridge University in both his undergraduate and graduate programs. He has since received a number of national and international dermatology scholarships and prizes

Benjamin F. McGraw, III, PharmD
Benjamin F. McGraw, III, PharmD

Chairman and Chief
Executive Officer
TheraVida, Inc.

View Biography

Ben McGraw’s background is in drug development and finance. He was responsible for the development side of R&D for what is now Sanofi US, he ran corporate development for Allergan and he’s been an analyst and a portfolio manager at 2 hedge funds. He’s run private and public biotech companies from seed to public commercial stages and has completed company sales, mergers, acquisitions and multiple licensing transactions. His current focus is selection, development and commercial positioning of early-stage drugs and biologics. He’s directly raised over $330 million in financings for early-stage companies and is currently involved in five companies where he is Chairman or Executive Chairman in 4 and a founding Director in the 5th. He completed a Bachelor of Science in pharmacy, a Doctor of Pharmacy, a clinical practice residency and multiple executive programs in business schools.

Seth Orlow
Seth Orlow, MD, PhD, FAAD

Senior Advisor
Pharus Advisors, LLC
Professor & Chair of Dermatology
NYU Grossman School of Medicine

View Biography

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Ethan Rigel
Ethan Rigel

Founding and Managing Partner
Gore Range Capital

View Biography

Ethan has 15 years of investing experience. He invested more than $900M in companies with a combined enterprise value of greater than $5B. Prior to founding Gore Range, Ethan Co-Founded NYBX, Inc. (LedgerX Holdings) serving as CFO. Ethan’s experience with fundraising through traditional venture capital avenues helped inspire his philosophy for Gore Range’s personal approach.

Ethan serves as a board member and advisor to DermX Media Group. For a decade Ethan has overseen the expansion of DermX’s offerings and the institutionalization of relationships with key dermatology industry partners. At Gore Range, Ethan serves on the boards of CoreMedica, Novaestiq, Or-Genix, Ornovi, Platform Imaging, and xMD. He is an observer on Dorsata and Novascan.

Ethan has two degrees from the MIT (B.S. in Economics & B.S. in Management Science) and a MBA from the Fuqua School of Business at Duke University.

Kristen B. Slaoui, PhD
Kristen B. Slaoui, PhD

Chief Corporate
Development Officer
Galderma

View Biography

Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Reid Waldman, MD
Reid Waldman, MD

Chief Executive Officer and Co-Founder
VeraDermics, Inc.

View Biography

Dr. Waldman is CEO and Cofounder of VeraDermics, Inc. a medical dermatology company focused on the development of innovative therapeutics that transform the standard-of-care across a broad range of common skin conditions. Dr. Waldman is a board-certified dermatologist by training. He received his Medical Doctorate from the University of Missouri-Kansas City and completed his residency in dermatology at the University of Connecticut. Since 2017, he has authored more than 100 peer-reviewed journal articles, abstracts, posters, and academic meeting presentations. Under his tutelage, VeraDermics Inc. has advanced the development of four dermatology-focused pharmaceuticals and raised more than $22M in equity financing.

Qiang (John) Wang, PhD, DVM
Qiang (John) Wang, PhD, DVM

Associate Vice President, External Innovation, Immunology
Eli Lilly and Company

View Biography

Qiang (John) Wang has been an Associate Vice President and Head of Immunology External Innovation at Eli Lilly since December 2018. Since joining Eli Lilly, John has identified and brought in numerous external innovation opportunities leading to several significant transactions including a $1.1 billion acquisition of Dermira in 2020, which internalized a Phase 3 program (Lebrikizumab) for the treatment of atopic dermatitis. Prior to joining Lilly, John worked at Merck Business Development and Licensing group and Sanofi External Innovation team. While being appointed as an Adjunct Assistant Professor at University of Pennsylvania School of Veterinary Medicine, John started his industry career as a Principal Research Scientist at Wyeth Research (Pfizer) Neuroscience, CVMD and Women’s Heath. John obtained a Veterinarian Degree from Qingdao Agricultural University College of Animal Science & Veterinary Medicine, China and a PhD in Pharmacology from University of London, St George’s Hospital Medical School, UK and conducted his postdoctoral training at both Harvard Medical School and Boston University.

Nick Williams, MPharm, PhD
Nick Williams, MPharm, PhD

Partner
Medicxi

View Biography

Nick is a Partner at Medicxi and is a Board Director of Vaderis, Versanis, Alderaan Biotechnology and Yukin Therapeutics. Prior to joining Medicxi, Nick co-founded a start-up urology company and worked in various business development and consulting roles for biotechnology companies.

Nick graduated with an MPharm from Cardiff University and completed his training at St George’s Hospital, London before returning to Cardiff to receive his PhD in urological drug delivery.

George D. Yancopoulos
George D. Yancopoulos, MD, PhD

Co-Founder, President, & Chief Scientific Officer
Regeneron

View Biography

George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer, has built Regeneron for nearly 35 years alongside President and Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D. Regeneron invents life-transforming medicines for people with serious diseases. Its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, all of which were homegrown in its laboratories, for a range of diseases, including cancer, vision-threatening eye diseases, asthma and infectious diseases. Dr. Yancopoulos is the holder of more than 100 patents and a principal inventor of Regeneron’s medicines and foundational technologies. He is the key driver of Regeneron’s unique science-driven culture and successful drug discovery and development engine, which encompasses industry leading antibody technologies as well as a diverse set of genetics medicine approaches.

After graduating as valedictorian at Bronx High and Columbia University, Dr. Yancopoulos received his M.D. and Ph.D. in Biochemistry and Molecular Biophysics from Columbia University. Later at Columbia, he served as legendary geneticist Dr. Fred Alt’s first post-doctorate student, working in molecular immunology. During his career, Dr. Yancopoulos has been the 11th most highly cited scientist in the world, was elected to both the National Academy of Sciences and the American Academy of Sciences and was elected as a Fellow by the American Association for the Advancement of Science (AAAS). In 2019, Dr. Yancopoulos was awarded Columbia College’s Alexander Hamilton Medal, the highest honor awarded to a member of the Columbia College community for distinguished service and accomplishment in any field of endeavor. In recognition of Regeneron’s work in developing a COVID-19 treatment, Dr. Yancopoulos was named on Fortune’s World’s 25 Greatest Leaders: Heroes of the Pandemic and received the Prix Galien Roy Vagelos Pro Bono Humanum Award for Global Health Equity and Business Council of Westchester’s Global Leadership Laureate Award along with Dr. Schleifer.

Karl Ziegelbauer, PhD
Karl Ziegelbauer, PhD

Chief Scientific Officer and Head of R&D
Almirall

View Biography

Karl currently serves as Chief Scientific Officer (CSO) and Head of R&D at Almirall, a global biopharmaceutical company focused on skin health based in Barcelona, Spain. He has three decades of leadership experience in drug discovery and early development gained in positions of increasing responsibility in international markets such as Germany, Japan, and the United States.

Before joining Almirall, Karl developed most of his career at Bayer Pharmaceuticals, holding Senior Vice President roles in various medical research fields. His experience encompasses different specialties such as oncology, cardiovascular diseases, anti-infectives, and immunology/inflammation.

Karl holds a PhD in Biochemistry from the University of Tübingen (Germany) and he has co-authored more than 50 scientific publications covering basic research as well as drug discovery topics.

Program

9:00AM

Registration and Networking Café

11:00AM

Networking Lunch

12:00PM

Program*

* Presentation order subject to change

State of the Industry
Dale Raine, PhD, Managing Director & Co-Head European Healthcare, Lazard

Featured Speaker – The history and future of Dupixent and Libtayo for skin disorders and cancers
George D. Yancopoulos, MD, PhD , Co-Founder, President, & Chief Scientific Officer, Regeneron

Featured Sponsor –
Hervé Hoppenot, Chairman, President, Chief Executive Officer, Incyte

Featured Sponsor – Transforming the Marketplace: The VTAMA Experience
Michael Cameron, MD, FAAD , Assistant Professor, Department of Dermatology, Mount Sinai Health System

The Dermatology Landscape
Frederick Beddingfield, III, MD, PhD, FAAD, Chief Executive Officer, Kira Pharmaceuticals; Associate Clinical Professor Medicine, UCLA
Seth Orlow, MD, PhD, FAAD, Senior Advisor, Pharus Advisors, LLC; Professor & Chair of Dermatology, NYU

Panel: Current Trends in Dermatology Partnering: Big Pharma vs. Derm Strategics
Moderated by Kristen Slaoui, PhD, Chief Corporate Development Officer, Galderma
Christophe Bourdon, Chief Executive Officer, LEO Pharma
Qiang (John) Wang, PhD, DVM, Associate Vice President, External Innovation, Immunology Eli Lilly and Company
Karl Ziegelbauer, PhD, Chief Scientific Officer and Head of R&D, Almirall

Panel: Why Venture Capital Companies Do or Don’t Invest in Dermatology
Ethan Rigel, Founding and Managing Partner, Gore Range Capital
Nicholas Williams, MPharm, PhD, Partner, Medicxi

Panel: Third Party Payers
Moderated by Benjamin McGraw III, PharmD, Chairman and Chief Executive Officer, TheraVida, Inc.

Entrepreneurial Company Showcase
AOBiome Therapeutics, Inc., Todd Krueger, President and Chief Executive Officer
AVAVA, Inc, Irina Erenburg, PhD, President and Chief Executive Officer
Azora Therapeutics, Matt Davidson, PhD, Co-Founder and Chief Executive Officer
Evelo Biosciences, Douglas Maslin, MPhil, MA, MB BChir, Vice President, Late-Stage Clinical Lead
MC2 Therapeutics A/S, Jesper J. Lange, Chief Executive Officer
Revelle Aesthetics, Caroline (Caro) Van Hove, President and Chief Executive Officer
Serpin Pharma, Cohava Gelber, PhD, MBA, Founder, President and Chief Executive Officer
Sibel Health, Steve Xu MD, MSc, FAAD, Chief Executive Officer
UNION therapeutics, Kim D. Kjoeller, MD, Chief Executive Officer
VeraDermics, Inc., Reid Waldman, MD, Chief Executive Officer and Co-Founder

6:00PM

Reception

People

Conference Board of Directors and Advisors

Frederick Beddingfield, III, MD, PhD, FAAD

Chief Executive Officer
Kira Pharmaceuticals
Associate Clinical Professor of Medicine, Division of Dermatology
David Geffen School of Medicine at UCLA

View Biography

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.

William Ju, MD, FAAD

President & Founding Trustee
Advancing Innovation in Dermatology, Inc.

View Biography

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.

Seth Orlow, MD, PhD, FAAD

Senior Advisor
Pharus Advisors, LLC
Professor & Chair of Dermatology
NYU Grossman School of Medicine

View Biography

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Kristen B. Slaoui, PhD

Chief Corporate Development Officer
Galderma

View Biography

Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Christina Weng, MD, FAAD

Senior Medical Director
Kira Pharmaceuticals

View Biography

Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is currently the Medical Director of Kira Pharmaceuticals, a Boston-based global biotech company developing innovative complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she serves as Chief Strategy Officer. As an Instructor in Dermatology at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital (MGH), she specializes in melanoma and pigmentary disorders.

Christina attended the California Institute of Technology, where she received her bachelor’s degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a medical fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral research was at the Cutaneous Biology Research Center of MGH.

Christina’s bench research has focused on melanocyte biology and mechanisms leading to pigment dysregulation, with an emphasis on clinically translatable opportunities in pigmentary disorders and melanoma. Her work additionally explores strategies for cutaneous drug delivery. Christina’s clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research support and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health.

Sponsors

Leadership

Incyte Dermatology

Premier

Dermavant

Major

Almirall
Lilly
Tergus

Supporting

Arcutis
Dow Development Laboratories
Evommune
Innovaderm
Maruho
MC2 Therapeutics
Verrica Pharmaceuticals

Founders

Aclaris
AID
Canfield
Palto
Pharus
For Sponsorship Opportunities, please contact Amanda Pacia at amanda.pacia@advancing-derm.org.

Networking

The Dermatology Summit utilizes a conference app for meeting materials and networking appointments, available on both Apple and Android devices for all registered attendees.

This app will also serve as our networking portal. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.

Our app will launch in December, and you will receive an email at that time with instructions.

Contact

General Inquiries

support@advancing-derm.org

Sponsorship Opportunities

Amanda Pacia
amanda.pacia@advancing-derm.org

Confirmed Speakers

Faye Silag
faye.silag@advancing-derm.org

Frequently Asked Questions

What is the agenda for the conference?

The current program agenda can be found here.

What is the cost of registration?

If registered by October 31, 2022 – $795
Registration after October 31, 2022 – $995

What is included in the registration fees?

Conference registration includes:

Health and Safety Release

Advancing Innovation in Dermatology, Inc. (“AID”) looks forward to welcoming attendees back in person for the 2023 Dermatology Summit scheduled for January 8, 2023. Health and safety remain a top priority, and AID is working with the Hyatt Regency San Francisco to plan for on-site precautions and mitigations for the event, including related to COVID-19.  Attendees should follow the CDC’s Isolation and Precautions for People with COVID-19 guidance, if they have tested positive for COVID-19 for any test done on or after December 28, 2022, or if they experienced symptoms of COVID-19 on or after December 28, 2022.

In all events, attendees must follow all federal, state and local health and safety guidance, including guidance on when to quarantine and wear a mask (AID reserves the right to update its health and safety policies in its discretion from to time to time). Of course, given the highly contagious nature of COVID-19 and its ability to spread by person-to-person contact, the event carries a risk of exposure to COVID-19 to attendees. By attending the event, attendees hereby agree to accept such risk and release and waive any and all claims, now known or hereafter known, against AID, its officers, directors, trustees, employees and agents, as well as its successors and assigns (collectively, the Releasees”) on account of any exposure to COVID-19 or any other illness or infection that may be associated with the event caused by any of the Releasees (except claims for willful misconduct or liability that cannot be released by applicable law).  

How do I become a Sponsor?

If you are interested in a sponsorship opportunity, please contact Amanda Pacia at amanda.pacia@advancing-derm.org, for the sponsorship overview and level pricing.

I am a confirmed speaker, now what?

Please check back for confirmed speaker deliverables or contact Faye Silag at faye.silag@advancing-derm.org.

Networking

Our app will launch in December, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.

Where can I make hotel reservations?

There are several hotels within a short distance from the Hyatt Regency, where the Dermatology Summit will take place. Please reference the list of hotels below for booking your own hotel room. The Dermatology Summit does not have contracted rates with these hotels.

Hotel Address Phone
Hyatt Regency San Francisco 5 Embarcadero Center 415-788-1234
Grand Hyatt San Francisco 345 Stockton Street 415-398-1234
Beacon Grand 450 Powell Street 866-377-9412
Westin St. Francis 335 Powell Street 415-397-7000
JW Marriott 515 Mason Street 415-771-8600
Hilton San Francisco Union Sq. 333 O’Farrell Street 415-771-1400
Ritz-Carlton 600 Stockton Street 415-296-7465
Marriott Union Sq. 480 Sutter Street 415-398-8900
What is the dress code?

Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.

I am a Sponsor. How do I redeem my contracted complimentary registration(s)?

After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by December 9, 2022. If you have not yet received the email, please contact Faye Silag at faye.silag@advancing-derm.org.

Cancellation Policy

Requests for registration fee cancellations for the conference must be received on or before December 9, 2022. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on December 9, 2022. Written notice of your cancellation should be sent to jamie.breslin@advancing-derm.org with a copy to support@advancing-derm.org.

Force Majeure

No damages or refunds shall be due for a failure of performance or because of a delay or cancellation of one or more of the AID Initiatives by the occurrence of any contingency beyond the reasonable control of Host. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, strikes, labor disputes, picketing or work stoppage (actual or threatened), an epidemic, pandemic or disease, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, change in meeting app ownership or management company, technology updates to the meeting app, interruptions or failure of the Internet, accessibility, connectivity or network connections, or any other acts beyond the reasonable control of the responsible parties.